C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Journal ArticleDOI
Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).
Lucia Masarova,Srdan Verstovsek,Francesca Palandri,Ruben A. Mesa,Claire N. Harrison,Gautam Sajeev,B. Gorsh,Sang Kyu Cho,Catherine E. Ellis,Sean P. Loveland Conlon,James Signorovitch +10 more
TL;DR: In this article , a matching-adjusted indirect comparison (MAIC) was performed to compare outcomes from phase 2 and/or 3 MMB and FED trials in patients with MF.
Journal ArticleDOI
Update in the myeloproliferative neoplasms.
TL;DR: Significant updates in the differential diagnosis of erythrocyosis and thrombocytosis are reported, presenting a simplified schema for the clinician.
Journal ArticleDOI
How We Treat Myeloproliferative Neoplasms
TL;DR: The present report focuses on management strategies for the myeloproliferative neoplasm according to the structure and processes within a large tertiary unit in central London, and how the unit has adapted to changes in the field.
Journal ArticleDOI
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Claire N. Harrison,Jyoti Nangalia,Rebecca H. Boucher,Aimee Jackson,Christina Yap,Jennifer O'Sullivan,Sonia Fox,Isaak Ailts,Amylou C. Dueck,Holly L. Geyer,Ruben A. Mesa,Natalia Curto-Garcia,Anna Green,Bridget S. Wilkins,Jason Coppell,John A. Laurie,Mamta Garg,Joanne Ewing,Steven Knapper,Josephine Crowe,Frederick Chen,Ioannis Koutsavlis,Anna L. Godfrey,Siamak Arami,Mark Drummond,Jennifer Byrne,Fiona Clark,Carolyn Mead-Harvey,Mary Frances McMullin,Adam J. Mead +29 more
TL;DR: The MAJIC-PV trial as discussed by the authors showed that ruxolitinib treatment benefits polycythemia vera patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to their knowledge, that molecular response is linked to EFS, PFS, and OS.